Should Immunosuppressive Therapy Be Modified During a Pandemic?

Bouffard, Marc A; Levy, Michael; Lee, Andrew G; Van Stavern, Gregory P

Bouffard, Marc A; Levy, Michael; Lee, Andrew G; Van Stavern, Gregory P.

Bouffard MA; Department of Neurology (MB), Beth Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; Department of Neurology (ML), Mass General and Harvard Medical School, Boston, Massachusetts; Ophthalmology (AL), Blanton Eye Institute, Houston Methodist Hospital, Houston, Texas; and Ophthalmology and Visual Sciences (GVS), St. Louis School of Medicine, Washington University, St. Louis, Missouri.

J Neuroophthalmol ; 41(2): 266-271, 2021 Jun 01.

Article in English | MEDLINE | ID: covidwho-1591872

Subject(s)

COVID-19/epidemiology; Eye Diseases/drug therapy; Immunosuppression Therapy/methods; Immunosuppressive Agents/therapeutic use; Pandemics; Comorbidity; Eye Diseases/epidemiology; Global Health; Humans

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Immunosuppression Therapy / Eye Diseases / Pandemics / COVID-19 / Immunosuppressive Agents Type of study: Observational study Limits: Humans Language: English Journal: J Neuroophthalmol Journal subject: Neurology / Ophthalmology Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google